BINPAT

UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases, particularly in the areas of immunology and neurology. They prioritize patient needs and strive to deliver impactful solutions that improve lives. This commitment is reflected in their Patient Value Strategy, which guides all aspects of their business, from research and development to delivery of therapies. Their company culture emphasizes care, considering the individual, not just the disease, and working to address needs beyond medicine.

UCB has a significant presence in the United States, with headquarters in Atlanta, Georgia, and research and development sites across the country. They are committed to driving innovation, promoting affordable access to medicines, and fostering diversity and inclusion within their workforce and clinical trials. UCB is dedicated to creating a sustainable future for patients and the planet, implementing green initiatives and prioritizing employee health and well-being.

UCB offers flexible work arrangements to its employees, including a hybrid model that allows for a balance between in-office and virtual work. This hybrid model requires employees to be in the office for a minimum of 40% of the time, with the remaining 60% devoted to virtual working. The company also offers Summer Fridays, allowing employees to stop working at 1 PM local time on Fridays, and encourages shorter meeting times to allow for transition and rest time. Additionally, they offer "recharge" days for employees to disconnect, rest, and recharge.

UCB offers a comprehensive benefits package to its employees, including medical, prescription drug, vision, and dental coverages; flexible spending accounts; death insurance; short- and long-term disability; legal assistance and identity theft plans; a wellness program; 401k and retirement savings plans; an Employee Assistance Program; employee discount programs; an Employee Stock Purchase Plan; and fertility benefits. UCB also offers a competitive vacation and time off policy, including a company-wide week-long closure during the end of the year holidays, and additional "recharge" days to encourage employees to disconnect, rest, and recharge. UCB has adopted a hybrid working model to provide employees with flexibility and balance, giving them the option to work remotely for a portion of their workweek. They also offer Summer Friday, allowing employees to leave early on Fridays, and encourage employees to plan meetings with short breaks in between to allow for transition and rest time.

UCB is a global biopharmaceutical company dedicated to creating value for people living with severe diseases, particularly in the fields of immunology and neurology. Their mission is to deliver moments that matter for patients by putting people at the heart of everything they do. This translates to a focus on scientific innovation, patient access, and a culture of care that strives to address the individual needs of patients beyond just providing medicine.

UCB promotes a culture of care and collaboration, centered on patient value and the pursuit of impactful solutions for those living with severe diseases. Their mission is to create an environment where employees are empowered to make ethical business decisions, supported by a comprehensive Ethics and Compliance program. They foster a sense of community by emphasizing open feedback, transparent conversations, and a diverse and inclusive workplace, with a focus on employee well-being, benefits, and career development.

UCB is committed to fostering a diverse, equitable, and inclusive workplace where all employees feel valued and respected. They believe in embracing the unique backgrounds, experiences, and perspectives of their employees to drive innovation and create value for patients. UCB's approach to diversity, equity, and inclusion (DE&I) is foundational to their sustainability approach, encompassing three key areas: diversity, equity, and inclusion. They define diversity as the richness of individual backgrounds and cultural experiences, equity as ensuring fair opportunities for development and advancement, and inclusion as respecting individual differences to drive impact. UCB prioritizes DE&I learning and application, engages employees through employee resource groups (ERGs), and leverages DE&I insights to inform their practices. They are actively working to improve representation in clinical trials and advocate for a more equitable life sciences industry.